IP Library › Granted Patent US 12,060,403
Granted Patent B2
US 12,060,403 · App. 16/756,756 · Granted Aug 13, 2024

Methods and compositions for treating and protecting against porcine reproductive and respiratory syndrome virus

Inventors: Raymond R. R. Rowland (Manhattan, KS); Ana Stoian (Manhattan, KS)
Assignee: Kansas State University Research Foundation
C07K14/705A01K67/027C12N15/85
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,060,403
App. No.
16/756,756
Granted
Aug 13, 2024
Kind
B2
Abstract

The present disclosure provides compositions and methods for decreasing permissiveness to infection by PRRSV. The methods involve inserting peptides or oligopeptides into the CD163 SRCR domain 5 to disrupt the protein structure and thereby prevent PRRSV infection. The deletion of the exon 13 region of PSTII eliminates infection. The replacement of cysteine residues with alanines in SRCR5 as a means to disrupt disulfide bond formation. The final method is the deletion of, or amino acid substitution within the SRCR4-5 interdomain region.

Claims (5)

1. A method of reducing susceptibility of a cell to infection by porcine reproductive and respiratory syndrome virus (PRRSV) comprising introducing a modification to the cell's genome, wherein the reducing susceptibility is in comparison to a cell that has not been modified, and wherein the modification comprise:

disrupting at least a portion of exon 13 sequence of CD163, wherein the modification does not comprise a disruption of exon 14 sequence of CD163, and wherein the modification is sufficient for the reducing susceptibility.

2. The method of claim 1 , wherein the modification results in deletion of at least 10 amino acids of a CD163 protein.

3. The method of claim 1 , wherein the modification comprises a complete deletion of the exon 13 sequence.

4. The method of claim 1 , wherein the cell with the modification is at least 50% less susceptible to the infection by PRRSV than the cell that has not been modified.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2021
From: ROWLAND, RAYMOND R.R.; STOIAN, ANNA
To: KANSAS STATE UNIVERSITY RESEARCH FOUNDATION
Reel/Frame 057198/0707 →
Continuity (2)
Provisional Application 62573078 · Oct 16, 2017
Related Publication 20210188939A1 · Jun 24, 2021
Cited By (1)
US 12,473,341